Fundamental Analysis of ALIGOS THERAPEUTICS INC(NASDAQ:ALGS) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALGS. ALGS was compared to 588 industry peers in the Biotechnology industry. ALGS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALGS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALGS had negative earnings in the past year.

In the past year ALGS has reported a negative cash flow from operations.

In the past 5 years ALGS always reported negative net income.

In the past 5 years ALGS always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -57.87%, ALGS is in line with its industry, outperforming 43.52% of the companies in the same industry.

ALGS has a Return On Equity (-95.22%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-57.87%
ROE	-95.22%
ROIC	N/A

ROA(3y)-59.28%

ROA(5y)-50.89%

ROE(3y)-85.72%

ROE(5y)-70.21%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALGS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALGS has more shares outstanding than it did 1 year ago.

ALGS has more shares outstanding than it did 5 years ago.

The debt/assets ratio for ALGS has been reduced compared to a year ago.

2.2 Solvency

ALGS has an Altman-Z score of -4.60. This is a bad value and indicates that ALGS is not financially healthy and even has some risk of bankruptcy.

ALGS has a Altman-Z score of -4.60. This is in the lower half of the industry: ALGS underperforms 62.46% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that ALGS is not too dependend on debt financing.

The Debt to Equity ratio of ALGS (0.00) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.6

ROIC/WACCN/A

WACC9.25%

2.3 Liquidity

A Current Ratio of 5.90 indicates that ALGS has no problem at all paying its short term obligations.

ALGS has a better Current ratio (5.90) than 61.95% of its industry peers.

ALGS has a Quick Ratio of 5.90. This indicates that ALGS is financially healthy and has no problem in meeting its short term obligations.

ALGS has a better Quick ratio (5.90) than 62.63% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.9
Quick Ratio	5.9

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALGS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.65%, which is quite impressive.

Looking at the last year, ALGS shows a quite strong growth in Revenue. The Revenue has grown by 11.65% in the last year.

EPS 1Y (TTM)29.65%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q56.86%

Revenue 1Y (TTM)11.65%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-24.27%

3.2 Future

The Earnings Per Share is expected to grow by 24.79% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 86.11% on average over the next years. This is a very strong growth

EPS Next Y46.43%

EPS Next 2Y21.41%

EPS Next 3Y11.62%

EPS Next 5Y24.79%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y86.11%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALGS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y21.41%

EPS Next 3Y11.62%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALGS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (5/3/2024, 1:13:56 PM)

0.7958

-0.05 (-5.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap60.22M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-57.87%
ROE	-95.22%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.9
Quick Ratio	5.9
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)29.65%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y46.43%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)11.65%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ALIGOS THERAPEUTICS INC (ALGS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens